To include your compound in the COVID-19 Resource Center, submit it here.

BMN 270 improves Factor VIII levels in Phase I/II for hemophilia A

Next quarter, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said it plans to start a pair of Phase III trials evaluating 4x1013 and 6x1013 vg/kg dose levels of BMN 270, an adeno-associated viral (AAV) vector delivering the Factor VIII gene, to treat severe hemophilia A. The company released its plans along

Read the full 481 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers